Skip to Content
 

News: Precision Cancer Medicine

Smoking study personalizes treatment

Thursday, November 16th, 2017

A simple blood test is allowing Vanderbilt University Medical Center (VUMC) researchers to determine which patients should be prescribed varenicline (Chantix) to stop smoking and which patients could do just as well, and avoid side effects, by using a nicotine patch.

My Cancer Genome launches new search tool for clinical trials

Friday, October 27th, 2017

My Cancer Genome (MCG), a web-based cancer information tool developed by Vanderbilt-Ingram Cancer Center investigators in 2011 and supported by GenomOncology, has launched a new clinical trial search tool that allows website visitors to search for cancer clinical trials based on disease, biomarker, phase and recruiting status.

Report identifies IT upgrades needed to enhance cancer care

Friday, August 18th, 2017

A group of nationally recognized medical information and data management experts has recommended the development of new knowledge software applications that work alongside electronic health record systems (EHRs) to help practicing oncologists access and use the latest genomic information to assist in the treatment of cancer patients. The recommendations were unveiled in a new report […]

Investigators match novel cancer mutations with potential therapies

Monday, August 7th, 2017

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]

PET imaging to predict tumor response

Thursday, June 15th, 2017

About 10 percent of patients with colorectal cancer express a mutated form of the signaling molecule BRAF, which may be targeted for treatment by selective BRAF inhibitors. PET (positron emission tomography) imaging using a standard glucose probe is not able to predict response to BRAF inhibitors. In addition to becoming dependent on glucose, cancer cells […]

Project reveals importance of cancer gene mutation testing

Friday, June 9th, 2017

An international genomic data-sharing consortium has analyzed nearly 19,000 patient genomic records and found that testing of patient tumors for relevant gene mutations often provides a roadmap for the use of effective therapies. The American Association for Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange (GENIE) is a multi-phase, multi-year data-sharing project launched in 2015 […]

Cancer Patient Chooses Nashville for VICC Care and the Nashville Predators

Friday, June 9th, 2017

Los Angeles native Christina Shaw had two powerful goals when she decided to move cross country to live in Nashville. The first was to support her favorite hockey team, the Nashville Predators, and the second was to meet with Leora Horn, M.D., M.Sc., a renowned lung cancer specialist at Vanderbilt-Ingram Cancer Center (VICC). Shaw, 33, […]

Annual Meharry-Vanderbilt-TSU Cancer Partnership retreat April 8

Friday, March 24th, 2017

The Meharry Medical College, Vanderbilt-Ingram Cancer Center (VICC) and Tennessee State University (TSU) Cancer Partnership will host its 16th Annual Cancer Retreat on Saturday, April 8, from 8:30 a.m. to 2:30 p.m. The retreat will be held on the Meharry Medical College campus in the Harold D. West Basic Sciences Building, Room M001. This year’s […]

Melanoma study finds new way to enhance targeted therapies

Friday, March 10th, 2017

With the help of a drug formerly used to treat HIV/AIDS, researchers at Vanderbilt University Medical Center (VUMC) have found a way to make melanoma cells more vulnerable to targeted anti-cancer therapy. Since the AIDS drug is already FDA approved, clinical testing in melanoma patients could potentially begin sooner than if it was a novel […]

Targeting the “un-targetable”

Thursday, December 1st, 2016

Triple negative breast cancers (TNBC) are so named because they lack common genetic “target” mutations that can be easily treated with specific cancer drugs. However, in a recent study published in Molecular Cancer Therapeutics, Deborah Lannigan, Ph.D., and colleagues investigated a new target involved in TNBC called RSK. They demonstrated that RSK can help cancers […]

Next Page »